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Major histocompatibility complex (MHC) class I molecules present short, perfectly cleaved peptides
on the cell surface for immune surveillance by CD8+ T cells. The pathway for generating these
peptides begins in the cytoplasm, and the peptide-MHC I (pMHC I) repertoire is finalized in the endo-
plasmic reticulum. Recent studies show that the peptides for MHC I are customized by the ER
aminopeptidase associated with antigen processing and by dynamic interactions within the MHC
peptide-loading complex. Failure to customize the pMHC I repertoire has profound immunological
consequences.Introduction
Immune surveillance by the CD8+ T cell repertoire requires
cells to display thousands of peptides, eight to ten amino
acids in length, bound to MHC I molecules (pMHC I) on
their surface. The peptides are derived from virtually all
proteins inside the cell and represent the otherwise invis-
ible intracellular milieu (Shastri et al., 2002). When the cell
is infected with a microbe or has been transformed into
a tumor, the pMHC I repertoire now also includes new
peptides derived from microbial or mutated self-proteins.
These peptides serve as flags for CD8+ T cells whose T
cell antigen receptors (TCRs) recognize the new pMHC I
and will eventually eliminate the infected or tumor cells.
The pMHC I-processing pathway produces this peptide
mixture from intracellular polypeptides, enables efficient
loading of peptide cargo onto the MHC I, and thereby
generates the pMHC I repertoire displayed on the cell
surface.
The pMHC I repertoire is generated by merging two
distinct cellular pathways. One pathway generates pep-
tide receptive MHC I molecules in the ER, whereas the
second pathway generates the peptides suitable for
loading the MHC I. The MHC I molecules are hetero-
dimers of a heavy chain and b2 microglobulin, both of
which are cotranslationally translocated into the ER.
Here, several chaperones and other specialized com-
ponents fold the two polypeptides and assemble the
heterodimer into the peptide-loading complex (PLC)
that keeps the MHC I molecules in a peptide-receptive
state. Concomitantly, the peptide generation pathway
begins in the cytoplasm, where newly synthesized poly-
peptides are fragmented and the peptide products are
shuttled into the endoplasmic reticulum via TAP, the
transporter associated with antigen processing. In the
ER, these peptides are further customized to yield the
final pMHC I repertoire that is eventually displayed on
the cell surface.
The pMHC I repertoire is composed of diverse pep-
tides—derived from recently synthesized proteins—thatare stably bound to the MHC I and persist on the cell
surface (Yewdell et al., 2003). Thus, sufficient time is
available for circulating CD8+ T cells to discover the ap-
propriate pMHC I on the surface of professional antigen-
presenting cells as well as infected or transformed cells.
The peptides that confer stability to pMHC I share two
important properties; a high-quality peptide is of the
precise length and amino acid sequence required for
a given MHC-I-binding motif. Until recently, it was be-
lieved that this optimal pMHC I repertoire was generated
primarily by the intrinsic peptide-binding properties of
MHC I molecules and the nature of the available peptide
pool. Recent discoveries provide a new perspective on
the customization mechanisms that optimize the pMHC I
repertoire.
The Cytoplasmic Peptide Pool Needs
Customization
In the cytoplasm, the multicatalytic proteasome and pos-
sibly tripeptidyl peptidase II and other proteases degrade
proteins into a mixture of peptides of variable lengths
(Rock et al., 1994; Paz et al., 1999; Kloetzel, 2004). Bio-
chemical analysis of this mixture in vitro as well as in living
cells has shown that the proper C termini of the final pep-
tides are efficiently generated in this compartment (Cascio
et al., 2001; Kunisawa and Shastri, 2003). The generation
of precise N termini is, however, not as stringent, and the
cytoplasmic mixture contains several proteolytic interme-
diates with a variable number of extra N-terminal-flanking
residues. These peptides are the precursors of the pMHC I
repertoire and arrive into the ER after TAP transport
(Neefjes et al., 1993). Because most of these peptides
do not yet have the precise N termini, they represent
‘‘rough drafts’’ that need editing and customization before
they yield the final pMHC I complexes.
It is important to emphasize that the substrates for
TAP transport and the resulting peptide pool in the ER
are extraordinarily diverse. The essentially conserved
cytoplasmic components of the antigen-processingImmunity 26, April 2007 ª2007 Elsevier Inc. 397
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ReviewFigure 1. Schematic Depiction of the
MHC I Peptide-Loading Complex
The MHC I molecule folds with the assistance
of the chaperones calnexin (not shown) and
calreticulin (CRT). Themultisubunit PLC is cen-
tered on TAP, the transporter associated with
antigen processing. The adaptor molecule
tapasin interacts with both TAP and the MHC
I molecules and forms a covalent disulfide
bond (S-S) with the oxidoreductase ERp57.
Protein disulfide isomerase (PDI) helps in for-
mation of the disulfide bond in the a2 domain
of the MHC I molecules. Whether ERAAP, the
ER aminopeptidase associated with antigen
processing, also interacts with the PLC is not
known. The cytoplasmic peptide pool contains
many antigenic precursors with N-terminal
extensions, which are removed after these
peptides are transported by TAP into the ER.
ERAAP trims these extensions, thus resulting
in the generation of the final pMHC I complex
that exits the ER and goes to the cell surface.pathway (Paulsson, 2004) cannot conceivably produce
peptides that accommodate the varied binding prefer-
ences of MHC I molecules waiting in the ER (Rammensee
et al., 1997). For example, the mouse Ld MHC I molecule
presents 9-mer peptides with the consensus motif
X[P]XXXXXX[I,L,M] (single letter amino acid code, X =
any amino acid), whereas the Kb MHC I molecule presents
8-mer peptides with the XXXX[Y,F]XX[I,L,M] motif (Falk
et al., 1991). Likewise, dozens of unique MHC-I-binding
motifs are known for different human alleles of HLA-A,
HLA-B, and HLA-C molecules (Rammensee et al., 1997).
Although exceptions to these motifs are known, these
consensus sequences represent the predominant amino
acid sequences of peptides eluted from each MHC I
molecule and define the general characteristics that favor
stable peptide binding to the MHC I. Generating these
large nonoverlapping sets of pMHC I presents a unique
challenge for the antigen-processing machinery.
The term ‘‘customization’’ is often used to describe the
mechanism by which MHC I molecules are preferentially
loaded with quality peptides in the ER. Historically, cus-
tomization has been ascribed to ER resident chaperones
and adaptor molecules, and many elegant studies have
contributed to our understanding of how these molecules
work (Figure 1). Although these proteins perform unique
and critical functions to facilitate the exchange of subop-
timal peptide cargo in favor of quality peptides, it should
not be overlooked that the effectiveness of these custom-
ization mechanisms depends on the composition of the
peptide pool available in the ER. Recent discoveries now
make it clear that the N termini of these peptides are cus-
tomized by ERAAP, the ER aminopeptidase associated
with antigen processing.
There are thus two potential mechanisms for customiz-
ing the pMHC I repertoire, one that acts on the MHC I
molecules and another that acts on their peptide cargo.
In the following sections, we discuss recent findings on
antigen-processing events in the ER and suggest that
the two mechanisms may not be mutually exclusive,
but rather work together to generate the final pMHC I
repertoire.398 Immunity 26, April 2007 ª2007 Elsevier Inc.Customizing the pMHC I Repertoire
in the Peptide-Loading Complex
The MHC I molecules are prepared for peptide loading in
the ER. With TAP at its center, a multisubunit structure
containing MHC I molecules, b2 microglobulin, tapasin,
calreticulin, ERp57, and possibly protein disulfide isomer-
ase is assembled in the ER (Figure 1). This structure is
called the peptide-loading complex (PLC) and has been
the topic of several excellent reviews (Cresswell et al.,
2005; Elliott and Williams, 2005; Garbi et al., 2007). Defi-
ciency in constituents of the PLC can have dramatic con-
sequences on the expression and quality of the pMHC I
repertoire on the cell surface. One mechanism by which
the PLC customizes the pMHC I repertoire involves selec-
tive ER retention of MHC I molecules, which are loaded
with suboptimal peptides (Sijts and Pamer, 1997; Lewis
and Elliott, 1998). ER retention thus provides an opportu-
nity for such peptides to dissociate from the binding
groove and be exchanged for quality peptides with higher
affinity for MHC I molecules. Tapasin, the adaptor that
connects TAP and MHC I molecules, is key to all of these
steps, and in its absence, the structure of the PLC is dis-
rupted and pMHC I are poorly expressed and suffer
from instability at the cell surface (Garbi et al., 2000;
Grandea et al., 2000). Several laboratories have demon-
strated that the overall contribution of tapasin to the
pMHC I repertoire is to maintain most MHC I polymorphs
in a peptide receptive state and to distinguish MHC I mol-
ecules associated with high- or low-affinity peptides and
enhance presentation of the former (Purcell et al., 2001;
Zarling et al., 2003; Howarth et al., 2004).
The mechanism by which this optimization is achieved,
either directly or indirectly, appears to involve the forma-
tion and maintenance of disulfide bonds within the MHC
I molecule. We discuss next recent findings on how oxido-
reductases contribute to the formation and customization
of the pMHC I repertoire.
Tapasin and ERp57
MHC I molecules have two disulfide bonds, one in the
a3 immunoglobulin-like domain and another in the a2
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is more susceptible to oxidoreductases (Tector et al.,
1997; Dick, 2004). Oxidation occurs early, prior to incor-
poration of MHC in the PLC, but retention in the ER and
optimization of peptide cargo requires the maintenance
of these disulfide bonds by shielding them from reduc-
tases and by reoxidizing them (Tector et al., 1997; Dick,
2004). The oxidoreductase ERp57, a stable component
of the PLC, has long been the suspect in these reactions
(Hughes and Cresswell, 1998; Lindquist et al., 1998; Mor-
rice and Powis, 1998). Chaperone-mediated oxidation or
reduction of disulfide bonds proceeds through a series
of electron-transfer events, which result in a transient co-
valent, disulfide-linked heterodimer between the oxidore-
ductase and its substrate. Resolution of the heterodimer,
termed the oxidoreductase escape pathway, allows the
appropriate disulfide-bond formation within the substrate
molecule and liberates the oxidoreductase from its sub-
strate. Although ERp57 normally operates in this manner,
within the PLC, the ERp57 oxidoreductase remains cova-
lently linked to tapasin (Figure 1) (Dick et al., 2002). Nonco-
valent interactions between the two proteins inhibit the
ERp57 oxidoreductase escape pathway, and therefore
the normally transient disulfide linkage is very stable (Pea-
per et al., 2005). Analysis of ERp57-deficient B cells and
studies involving mutant tapasin molecules that fail to
covalently bind ERp57 suggest that this unusually stable
heterodimer between an oxidoreductase and its substrate
is required for structural integrity of the peptide-loading
complex and for promoting customization of pMHC I.
Hammerling and colleagues have recently described
that the assembly of MHC I into the PLC is severely
impaired (5%–10% that of the wild-type, WT) in ERp57-
deficient B cells, and these molecules disassociate from
the PLC and exit the ER at an accelerated rate (Garbi
et al., 2006). The result of ERp57 deficiency on surface ex-
pression and stability of pMHC I is, however, dependent
on the particular MHC I. The Kb but not Db-peptide com-
plexes disassociate from the cell surface at an increased
rate, indicating that some of these pMHC I contain subop-
timal peptides. Importantly, the absence of ERp57 impairs
the incorporation of calreticulin into the PLC by approxi-
mately 50%, and the defects of ERp57-deficient cells, in-
cluding the Kb MHC-specific impact, are similar to those
of calreticulin-deficient cells (Gao et al., 2002). The con-
verse, however, is not true; in the absence of calreticulin,
ERp57 and MHC I assemble normally into the PLC, and
this suggests that ERp57 itself can provide structural in-
tegrity to the PLC, perhaps by modulating the tapasin-
MHC I interaction.
Whether the oxidoreductase ERp57 acts directly on the
a2 disulfide bond of MHC I has been much debated (Dick,
2004; Garbi et al., 2007). Because the oxidation state of
MHC I molecules is unchanged in the ERp57-deficient
cells, it is suggested that ERp57 does not directly oxidize
the disulfide bonds inMHC I. However, whether ERp57 re-
duces these bonds, which would not occur in the absence
of ERp57, still remains an open question. Evidence in favor
of this hypothesis has been provided by studies of mutanttapasin molecules, which fail to form ERp57 conjugates.
Under such conditions, MHC I molecules suffer from par-
tial reduction and are somewhat less stable (Dick et al.,
2002), although this defect may be specific for certain
MHC I polymorphs (Howarth et al., 2004). Taken together,
these studies indicate that tapasin restrains ERp57 from
reducing MHC I, and reduction can interfere with optimi-
zation of peptide cargo.
Oxidation of MHC I by Protein Disulfide Isomerase
If reduction of the a2 disulfide bond in MHC I precludes
optimization of the peptide cargo, how is this bond oxi-
dized? Ahn and colleagues have provided compelling ev-
idence that protein disulfide isomerase (PDI), long known
as a ubiquitous catalyst of protein disulfide-bond forma-
tion in the ER, as a key regulator of the oxidation state of
MHC I molecules and optimization of its peptide cargo
(Park et al., 2006). The authors identified PDI as a compo-
nent of the PLC in several cell lines and also directly
showed that MHC I is a substrate for the PDI oxidoreduc-
tase. Indeed, a transient, covalent conjugate between the
two proteins is found both inside and outside of the PLC.
In cells depleted of PDI, the pMHC I mature slowly, are
40% reduced at the cell surface, and are loaded with sub-
optimal peptides. The authors also reported that in HeLa
cells, MHC I molecules remain fully oxidized when assem-
bled into the PLC. In the absence of PDI, however, some
MHC I molecules within the PLC are reduced (Park
et al., 2006). These results suggest that within the PLC,
PDI keeps the a2 domain of MHC I oxidized to facilitate
expression of MHC I molecules at the cell surface and op-
timization of its peptide cargo (Figure 1).
This study also described another layer, of oxidative
regulation, that is dependent on peptide supply to the
ER. In HeLa cells, blocking TAP transport results in an in-
crease in the relative amount of MHC I molecules found in
reduced form as well as the amount of PDI-MHC I conju-
gates (Park et al., 2006). The dynamics of TAP itself within
the ER is linked to peptide supply and active translocation
(Reits et al., 2000). Thus, whether MHC I molecules are re-
duced under these circumstances because PDI requires
TAP translocated peptides for proper function is unclear.
Notably, rescue of pMHC I expression in PDI-depleted
cells requires both the catalytic domain and a functional
peptide-binding domain of PDI (Park et al., 2006). That
peptides are bound to cytoplasmic and ER-localized pro-
tein chaperones has long been appreciated (Spee and
Neefjes, 1997; Srivastava, 2002), and it is likely that such
association protects peptides from degradation (Shastri
et al., 2005). Whether chaperone–peptide interactions
serve as a delivery mechanism either to TAP or, in this
case, to the binding groove of MHC I molecules is not
known. It remains possible that the peptide-binding do-
main of PDI is required for some other reason, such as rec-
ognition of its protein substrates or recruitment into the
PLC. In any case, it is clear that the oxidation state of
MHC I molecules within the PLC is dynamic and that load-
ing of MHC I with optimal peptides requires formation and
maintenance of the a2 disulfide bond that forms theImmunity 26, April 2007 ª2007 Elsevier Inc. 399
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ing it from reduction via covalent sequestration of ERp57
by tapasin or oxidation by PDI.
The operating principle for customization of peptide
cargo by ER chaperones is that the dynamics of the PLC
provide sufficient time for suboptimal, weakly bound pep-
tides to be replaced by higher-affinity, quality peptides
and thus allow the generation of stable pMHC I. We now
know that MHC I do not need to siphon such peptides
from the milieu of ‘‘rough drafts’’ that arrive from the cyto-
plasm. Rather, customization of the peptide pool and
the generation of quality peptides can occur in the ER it-
self by ERAAP-mediated trimming. We discuss the dis-
covery and manifestations of this proteolytic customiza-
tion step next.
Customizing Peptides in the ER
It is now clear that proteolysis continues in the ER, and
peptide precursors with extra amino- but not carboxy-ter-
minal residues are efficiently trimmed in this compart-
ment. The existence of this trimming step was inferred in
several early studies (discussed in Serwold et al. [2001]).
These include observations suggesting existence of dis-
tinct proteases in the cytoplasm and in the ER (Craiu
et al., 1997), as well as those showing that microsomes
contained aminopeptidase(s) activity that could trim anti-
genic precursors in vitro (Brouwenstijn et al., 2001; Fruci
et al., 2001; Komlosh et al., 2001).
Compelling evidence for an ER aminopeptidase
emerged from the serendipitous observation that when
flanked by additional N-terminal residues, proline but no
other amino acid blocks processing of peptides and gen-
eration of pMHC I from these precursors (Serwold et al.,
2001). This suggested that an aminopeptidase may be in-
volved because the inability to cleave the ‘‘X-P’’ bond is
a characteristic property of this class of proteases. Fur-
thermore, it was intriguing that approximately 20% of
known consensus motifs for MHC I contained a proline
residue at the p2 position (‘‘X-P’’, for example Ld MHC I),
yet studies on the substrate specificity of TAP had shown
that it did not transport ‘‘X-P’’ peptides (Neisig et al., 1995;
Van Endert et al., 1995). For resolving this conundrum it
was postulated that the substrates for TAP were peptides
with extra N-terminal residues flanking the ‘‘X-P’’ pep-
tides. Because proline would no longer be at the p2 posi-
tion, TAP transport would be efficient, but these precur-
sors would necessarily require trimming in the ER to
allow their presentation as ‘‘X-P’’ peptides by the appro-
priate MHC I. Indeed expression of several different
pMHC I, and especially Ld, which presents peptides with
the ‘‘X-P’’ motif, was dramatically lower in cells treated
with aminopeptidase inhibitors (Serwold et al., 2001).
Thus, aminoterminal trimming occurred in the ER, not
only for ‘‘X-P’’ precursors but also for other peptides.
The enzyme responsible for this trimming was sub-
sequently identified as ERAAP, the ER aminopeptidase
associated with antigen processing in mice (Serwold
et al., 2002), and ERAP1 in the human (Saric et al., 2002;
York et al., 2002). The ERAAP was coexpressed in all cells400 Immunity 26, April 2007 ª2007 Elsevier Inc.with MHC I and was upregulated by interferon-g (IFN-g),
a proinflammatory cytokine that enhances antigen
presentation. Furthermore, ERAAP trimmed N-terminal
amino acids, with the exception of ‘‘X-P’’ residues, from
peptides in vitro, and ERAAP inhibition in cell lines altered
pMHC I presentation. Thus, ERAAP had a role in the pro-
cessing of peptides presented by MHC I.
Further insights into how peptide customization in the
ER regulates the pMHC I repertoire came from analysis
of mice lacking ERAAP.
ERAAP Deficiency Alters the pMHC I and MHC
Class Ib Repertoires
Mice lacking ERAAP were generated in several laborato-
ries. As predicted by earlier studies, the expression of
the ‘‘X-P’’-presenting Ld MHC I molecules, as measured
by flow cytometry, drops dramatically by 80% in cells
lacking ERAAP (Hammer et al., 2006). To a lesser extent,
expression of other MHC I molecules is also reduced,
and pMHC I are less stable when compared to those ex-
pressed in wild-type cells. Examination of the expression
of individual peptides with a panel of CD8+ T cell hybrid-
omas showed that ERAAP deficiency left some peptides
unaffected, whereas others were either absent or dramat-
ically upregulated. We refer to these peptides as Ei, Ed,
and Es because they are, respectively, ERAAP inde-
pendent, dependent, or sensitive (Figure 2). Differences
were also noted in the ability of ERAAP-deficient mice
to respond to minor histocompatibility antigens. Subse-
quently, similar changes in the pMHC I repertoire of ERAAP-
deficient mice and its impact on the CD8+ T cell responses
were reported by the laboratories of van Kaer, Rock, and
Niedermann (Yan et al., 2006; York et al., 2006; Firat et al.,
2007). Thus, ERAAP deficiency disrupts the normally
diverse pMHC I repertoire and influences CD8+ T cell
responses.
The nonclassical class I molecules Qa-1 and Qa-2 bind
and present peptides in a TAP-dependent and, as de-
scribed by van Kaer and colleagues, also ERAAP-depen-
dent manner (Yan et al., 2006). Expression of Qa-2 mole-
cules, which bind a diverse set of nonamer peptides, is
reduced by 30% on ERAAP-deficient cells, akin to the de-
fect observed for classical MHC I molecules. In contrast,
expression of Qa-1 is unchanged and may even increase
slightly. Even so, ERAAP deficiency decreases the ex-
pression of Qdm, the nonamer peptide that is the predom-
inant cargo of Qa-1 molecules and serves as a ligand for
a subset of natural-killer cells (Vance et al., 1999). The
peptide(s) that replace Qdm in ERAAP-deficient cells are
presently unknown but could be rather abundant because
expression of Qa-1 on the cell surface is comparable to
that of WT cells. Perhaps, like the ERAAP-sensitive pep-
tides for classical MHC I, ERAAP trimming also limits the
amount of peptides available for Qa-1 binding (Hammer
et al., 2006). The identity of the peptide presented by
Qa-1 and whether Qa-1 restricted CTL responses or nat-
ural-killer-cell populations are influenced by ERAAP re-
main to be addressed.
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Major Changes in the Conventional
pMHC I Repertoire and Causes the
Generation of a Unique and Novel set
of pMHC I
The antigen-processing pathway generates
a diverse set of peptides in wild-type mice
(top). Some of these peptides are expressed
at similar amounts (ERAAP-independent, Ei-p)
in ERAAP-deficient mice (bottom), whereas
certain peptides (ERAAP-sensitive, Es-p) are
increased several hundred fold. Other peptides
(ERAAP-dependent, Ed-p) are missing be-
cause ERAAP is required to trim them to their
final form from N-terminally extended precur-
sors. These Ed-pMHC I induce CD8+ T cell re-
sponses in ERAAP-deficient mice because the
absence of these peptides precludes T cell
tolerance. In contrast, the ERAAP-unedited
novel peptides (Eun-p) are unique to ERAAP-
deficient cells and elicit robust CD8+ T cells
as well as B cell antibody responses when
injected into wild-type mice. It is likely that
Eun-pMHC I arise from the pool of N-terminally
extended Ed-p precursors that fail to be
trimmed in the absence of ERAAP, a key com-
ponent of the antigen-processing pathway.That disruption of the pMHC I repertoire was due to the
loss of peptide trimming in the ER compartment itself was
shown in cells derived from TAP and ERAAP-double-defi-
cient mice (Hammer et al., 2006). In the absence of TAP,
peptides from the cytoplasm cannot enter the ER unless
they are introduced into this compartment by the addition
of an upstream ER-localization-signal sequence. Under
these conditions, generation of pMHC I is entirely depen-
dent upon ER proteases. Precursors with extra N-terminal
flanking residues are not trimmed in the absence of
ERAAP, but peptides requiring no further processing are
presented at wild-type levels. Thus, ERAAP-dependent
pMHC I (Ed-pMHC I) are likely to have been generated
from precursors that arrived in the ER with N-terminal
extensions and require ERAAP trimming. Furthermore, in
the ER, ERAAP is the predominant protease for trimming
peptides for MHC I molecules because its absence is
not compensated by another protease.
Further evidence that ERAAP serves a unique function
in the MHC I antigen-processing pathway came by the
use of CD8+ T cells for detecting differences between
the pMHC I repertoire of WT or ERAAP-deficient cells
(Hammer et al., 2007). If the pMHC I repertoire of ERAAP-
deficient mice was absolutely missing peptides normally
expressed in WT mice, the ERAAP-deficient mice would
not be tolerant to these peptides. Indeed, when immu-
nizedwithWT cells, ERAAP-deficient micemount a robust
CD8+ T cell response specific for peptides presented by
either Kb or Db MHC I. Although the precise identity and
diversity of these Ed-pMHC I remain to be determined, it
is clear that ERAAP serves a nonredundant function intrimming N-terminal extensions from precursor peptides
in the ER.
In contrast to mice, humans express another ER amino-
peptidase, termed L-RAP or ERAP2 (Tanioka et al., 2003).
Like ERAAP (or ERAP1), L-RAP (or ERAP2) was abundant
in the spleen, but expression of the two enzymes did not
correlate in other tissues such as the thymus or liver (Ser-
wold et al., 2002; Tanioka et al., 2003). In vitro assays have
shown that L-RAP can trimN termini of synthetic peptides,
and simultaneous knockdown via siRNA of both enzymes
lowers surface pMHC I expression on HeLa cells more so
than knockdown of either protease alone (Saveanu et al.,
2005). Interestingly, a fraction of the two aminopeptidases
is present in heterodimeric form in human cell lines, al-
though their enzymatic activity has not yet been reported.
When assayed in vitro, ERAP1 and L-RAP can comple-
ment each other in trimming amino acids from a precursor
peptide and thereby accelerate the production rate of
the final peptide. It should be interesting to determine
the consequences of selective deficiency of either one
or both ERAP1 and L-RAP on the pMHC I repertoire in
humans.
How Does ERAAP Trim Precursor Peptides?
If cytoplasmic proteolysis yields the ‘‘rough draft’’ of the fi-
nal peptide, how are peptides edited in the ER? ERAAP
may work as a ‘‘molecular ruler’’ and preferentially trim
peptide precursors to the final length required for binding
MHC I molecules. Alternatively, the MHCmolecules could
somehow regulate ERAAP such that it would trim only the
extra ‘‘overhanging’’ amino acids.Immunity 26, April 2007 ª2007 Elsevier Inc. 401
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suggest that it could specialize in processing peptides
for MHC I. Most notably, 9-mer and 8-mer peptides are
poorly trimmed by ERAAP, and peptides of this length per-
sist as end products from longer peptide substrates (Saric
et al., 2002; Serwold et al., 2002; York et al., 2002). In an
extensive analysis of ERAAP’s substrate specificity, Gold-
berg and colleagues used a panel of peptides of various
lengths and found that peptides of 9–16 amino acids
were preferred over peptides of longer or shorter lengths
(Chang et al., 2005). On the basis of this length preference
that is not shared by the other aminopeptidases tested, in-
cluding L-RAP (ERAP2), they suggested that ERAAP could
serve as a unique ‘‘molecular ruler’’ to generate the 8- and
9-mer peptides preferred by MHC I molecules.
In the same study, Goldberg and colleagues described
that ERAAP trimming and substrate selection could also
be affected by the identity of the C-terminus of the peptide
precursor (Chang et al., 2005). They analyzed a panel of
10-mer peptides, variable only at the C terminus, as
ERAAP substrates. During a 1 hr incubation time, the
rate at which aminoterminal residues were removed was
accelerated as much as 20-fold for peptides with hydro-
phobic versus basic C termini. This bias for peptides
with hydrophobic C termini remarkably coincides with
the binding motif of many MHC I molecules. Thus, by se-
lectively trimming only those peptides that would be useful
for presentation, ERAAP could determine not only the N
terminus, as it can for ‘‘X-P’’ peptides, but also the C ter-
minus of the peptides.
Several observations, however, detract from this attrac-
tive model. First, many human MHC I (e.g., HLA-A*1101
and A*6801) are known to present peptides with basic
amino acids at their C terminus (Rammensee et al.,
1997). If ERAAP is incapable of generating such peptides,
it implies that another aminopeptidase with similar length
preferences, but with a bias for basic C termini would be
required to generate the full-spectrum of peptides for
this set of human MHC I. That L-RAP could serve this
role is an attractive possibility. Second, in vivo analysis
of peptides that were trimmed by ERAAP did not reveal
a length preference. For example, the 9-mer peptides de-
rived from the H13 and H3a minor histocompatibility anti-
gens are trimmed and destroyed by ERAAP, but another
9-mer derived from ovalbumin is not (Hammer et al.,
2006). Finally, analysis of the fate of antigenic precursors
in vivo (see below) strongly suggests that the MHC mole-
cules themselves play a role in the generation of the final
peptides (Kanaseki et al., 2006).
It is also important to note that ERAAP’s enzymatic ac-
tivity in vitro is remarkably inefficient; peptide trimming by
recombinant or purified ERAAP requires long (in the order
of hours) incubations versus the shorter time (minutes)
in which peptide precursors are trimmed in microsomes
or in living cells (Brouwenstijn et al., 2001; Fruci et al.,
2001; Komlosh et al., 2001; Reits et al., 2003). Thus, ex-
periments in vitro, while providing a testable framework
for ERAAP’s specificity, may lack the necessary compo-
nents that allow rapid and efficient trimming in vivo.402 Immunity 26, April 2007 ª2007 Elsevier Inc.The Template Model for ERAAP Trimming
Our recent study suggests that in the ER of living cells,
MHC I molecules contribute to ERAAP’s activity by regu-
lating the generation of the final peptides (Kanaseki et al.,
2006). The fate of a 15-mer precursor that yields a 9-mer
peptide presented by Ld MHC I was examined in TAP-
ERAAP-double-deficient cells. In the absence of ERAAP,
the N-terminally extended, untrimmed 15-mer precursor
is readily detected in cell extracts. When ERAAP is co-
expressed, independent of Ld MHC, the precursor is
trimmed and is no longer detectable. This result conclu-
sively demonstrated that in vivo, ERAAP’s enzymatic ac-
tivity does not require the appropriate MHC I. Yet, despite
efficient trimming of the precursor, the abundance of the
9-mer product is extremely low, probably because of fur-
ther trimming and thus destruction of the final peptide by
ERAAP. In contrast, in the presence of Ld MHC, the
amount of the final 9-mer peptide is increased by approx-
imately 600%. These findings indicate that generation of
the final peptide is most efficient in the presence of the
appropriate MHC I and ERAAP, suggesting a synergy
between the two molecules. This synergy is likely to regu-
late or preclude destructive ERAAP trimming of the final
peptide once it has been generated.
How do MHC I molecules regulate peptide processing?
Current evidence is consistent with a template model by
which MHC I molecules modulate peptide trimming. Orig-
inally proposed by Rammensee and colleagues (Falk
et al., 1990), this model suggests that in the ER, MHC I
molecules can bind precursor peptides. Perfectly sized
peptides can then be tailor made if ERAAP removes those
amino acid residues that extend beyond the binding
groove of the MHC I-precursor-peptide template. MHC I
molecules bound to N-terminally extended, precursor
peptides have indeed been found in microsomes in vitro
(Brouwenstijn et al., 2001), and it is now shown that
such a ‘‘template-complex’’ also exists in living cells (Ka-
naseki et al., 2006). An N-terminally extended version of
the 9-mer peptide discussed above was found to bind
Ld MHC, suggesting that such complexes could serve
as potential substrates for ERAAP in vivo. This would pre-
clude destructive trimming by ERAAP and concomitantly
permit the generation of the final 9-mer pMHC I. Collec-
tively, these studies suggest that ERAAP trimming activity,
although not strictly dependent upon MHC I, can be more
efficient by virtue of a ‘‘template-complex’’ within which
precursor peptides are bound to MHC I molecules and
trimmed to their final size. Although the putative precur-
sors bound to MHC I have been detected, whether they
serve as ERAAP substrates in vivo remains unclear.
If ERAAP trimming is regulated by MHC I, then its effi-
ciency should also depend on the PLC, which not only se-
questersMHC I in the ER but also facilitates customization
of the peptide repertoire. We reasoned that if ERAAP effi-
ciency was regulated by the PLC, ERAAP trimming would
be compromised in the absence of tapasin, which is key
to structural integrity of the PLC. Naturally processed pep-
tides from tapasin-deficient or wild-type spleen cells were
extracted, and the amount of H13 and Uty-derived
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tively ERAAP-dependent or ERAAP-sensitive (Hammer
et al., 2006), were measured. Tapasin deficiency altered
the expression of these two peptides in a manner consis-
tent with impaired ERAAP function. The relative amount of
the H13-derived, ERAAP-sensitive peptide doubled in the
absence of tapasin, whereas the Uty-derived, ERAAP-
dependent peptide was reduced by 95% compared to
the wild-type (unpublished data). Perhaps tapasin, either
by direct association with ERAAP or by facilitating assem-
bly of the PLC, enables the synergy between MHC I and
ERAAP.
Why Are Some Peptides ERAAP-Sensitive?
Given that MHC I bind and protect the final, perfect pep-
tide once generated, why is ERAAP trimming deleterious
to some peptides? Again, the answer may involve the
MHC I molecules, in this case, how tightly a given peptide
is bound and will remain bound to MHC I in the ER. It is
reasonable to envisage that peptides bound with low af-
finity, which give rise to unstable pMHC I complexes at
the cell surface, may also be unstable in the ER. Com-
pounding the inherent instability of these pMHC I are the
customizing mechanisms employed in the PLC wherein
low-affinity peptides preferentially disassociate from the
peptide-binding groove. As discussed above, such ‘‘free’’
peptides (those not bound to MHC I) can be trimmed
and destroyed by ERAAP (Kanaseki et al., 2006). Thus,
unstable pMHC I would be particularly vulnerable to
destructive ERAAP trimming. This model may also explain
why tapasin-deficient cells increase expression of ERAAP-
sensitive peptides such as the H13-derived peptide,
which bindsDbweakly (Ostrov et al., 2002). Because tapa-
sin facilitates the release of low-affinity peptides from
MHC I, and these ‘‘free’’ peptides can be degraded by
ERAAP, the presentation of ERAAP-sensitive Es-peptides
(Es-p) is enhanced because the Es-pMHC I are more sta-
ble in the ER in the absence of tapasin-mediated disasso-
ciation of these complexes. Thus, sensitivity to ERAAP
trimming could be related to how well the peptides are
bound by MHC.
To our knowledge, there is currently no evidence that
ERAAP physically interacts with the PLC. Nevertheless,
from what we have learned about customization of the
peptide pool in the ER, it would be interesting to examine
how the PLC and ERAAPmight coordinate to generate the
final pMHC I repertoire.
ERAAP-Unedited Novel Peptides
Perhaps the most surprising finding on the role of ERAAP
in customizing the pMHC I repertoire was the discovery of
unique peptides presented by MHC I exclusively by
ERAAP-deficient cells (Hammer et al., 2007). Wild-type
C57BL/6 (B6 or WT) mice elicit a robust CD8+ T cell re-
sponse when immunized with spleen cells from ERAAP-
deficient, B6 mice. Notably, the CD8+ T cell response
is comparable in magnitude to that elicited by MHC-
mismatched allogeneic cells. The immunogenicity of
ERAAP-deficient cells in WT mice was unexpected be-cause the disruptions to the pMHC I repertoire had previ-
ously shown only the loss of some pMHC I and increased
expression of others (Figure 2). Because all these pMHC I
are nevertheless present in WT mice, the CD8+ T cells
should be tolerant to these self-pMHC I. Surprisingly, un-
like the response to conventional pMHC I, the CD8+ T cell
response to ERAAP-deficient cells is not inhibited by con-
ventional pMHC I antibodies, suggesting that the T cells
recognize a distinct set of peptide ligands (Hammer
et al., 2007). Nevertheless, ligand expression requires
TAP as do conventional pMHC I. Most importantly, ligand
expression is induced in WT but not MHC I-deficient cells
by treatment with leucinethiol, a potent inhibitor of ERAAP.
Thus, although unusual, these CD8+ T cell ligands are
nevertheless a novel set of pMHC I that are unique to
the repertoire expressed by ERAAP-deficient cells. We re-
fer to these ligands as ERAAP-unedited novel peptides
(Eun-p, Figure 2).
What are the characteristics and origin of Eun-p? Unlike
Ei, Ed, and Es peptides, which are the usual eight to nine
amino acids in length, the Eun-p are likely to be longer in
length because they are rather unstable at the cell surface
(Hammer et al., 2007). Moreover, WT mice elicit an anti-
body response to ERAAP-deficient cells, and to our
knowledge this is unprecedented in MHC-matched
mice, and further establishes Eun-pMHC I as structurally
and immunologically unique. A monoclonal antibody was
derived from the immune WT mice; this antibody recog-
nizes an abundant epitope expressed on all ERAAP-
deficient but not ERAAP-heterozygous or WT spleen
cells (Hammer et al., 2007). Like the CD8+ T cell ligands
described above, expression of the antibody epitope re-
quires the expression of TAP andMHC I molecules. These
findings considered together with the inability of conven-
tional pMHC I antibodies to engage Eun-pMHC I strongly
support the notion that Eun-pMHC I are derived from
a novel set of peptides that are presented at the cell sur-
face in a unique structural configuration that does not exist
in cells with functional ERAAP. That dearth of ERAAP en-
zymatic activity is necessary for Eun-pMHC I expression
suggests that these complexes represent N-terminally ex-
tended precursors of Ed-pMHC I or other ‘‘rough drafts,’’
which are normally trimmed by ERAAP (Figure 2).
Will Eun-pMHC I serve as targets for CD8+ T cell re-
sponses to intracellular pathogens? Increased suscepti-
bilty of ERAAP-deficient mice to pathogenic viruses has
not yet been observed (Yan et al., 2006; York et al.,
2006; Firat et al., 2007) but remains a possibility especially
for responses dependent on Ld or other MHC I that bind
ERAAP-dependent ‘‘X-P’’ peptides. Owing to instabilitiy
of Eun-pMHC I, CD8+ T cells recognizing these ligands
may be inefficiently primed, may remain poor effectors,
or may be deficient in memory responses.
How are the Eun-p bound by MHC I and recognized by
the TCR? There are occasional reports of long peptides
that are recognized by CD8+ T cells and whose struc-
tures have been determined. Intriguingly, each of these
peptides, the longest of which is a 14-mer, contains a
proline residue at the p2 position and is presented byImmunity 26, April 2007 ª2007 Elsevier Inc. 403
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motif (Probst-Kepper et al., 2001; Green et al., 2004). As
discussed above, the X-P bond is not trimmed in the ER,
and thesepeptides remain asend-products of ERAAPpro-
cessing (Serwold et al., 2001; Serwold et al., 2002). Thus, it
is possible that precursors of these peptides arrive in the
ER with varying N-terminal extensions as demonstrated
in other model systems (Paz et al., 1999; Kunisawa and
Shastri, 2003) and are trimmed by ERAAP until it encoun-
ters the resistant ‘‘X-P’’ bond. Presentation of long ‘‘X-P’’
peptides that are refractory to ERAAP trimming perhaps
recapitulates Eun-pMHC I, which are expressed when
ERAAP is absent. To accommodate the aforementioned
peptides into HLA-B*3501molecules, the peptide ‘‘bulges’’
in thecenter of thepeptide-bindinggroove (Probst-Kepper
et al., 2004; Tynan et al., 2005) and in one case has been
shown to be ‘‘bulldozed’’ when bound to the TCR (Tynan
et al., 2007). Whether the structurally distinct Eun-pMHC
I complexes and their interactions with the TCR will share
similar principles remains to be determined.
The expression of Eun-pMHC I by ERAAP-deficient
cells also argues against the long-held belief that the con-
sensus motifs that define MHC I presentation result from
selective peptide binding. The fact that Eun-pMHC I
were generated in the presence of all the other PLC com-
ponents shows that the PLC cannot by itself customize
peptide cargo to ensure presentation of the normal
pMHC I repertoire. Clearly, ERAAP is an additional key
player and a quintessential editor that performs the final
cuts to make the pMHC I repertoire perfectly customized.
Conclusions and Future Perspective
The discoveries of dynamic oxidation and reduction reac-
tions in the PLC and peptide trimming by ERAAP have pro-
vided new insights into how cells generate their pMHC I
repertoire. Compelling evidence indicates that the PLC
and ERAAP shape the pMHC I repertoire, the PLC by pro-
moting the association of MHC I with high-affinity, quality
peptides and ERAAP by trimming precursors of these
peptides to their final length. If trimming were to occur
while the precursor peptides are bound to the MHC I,
then ERAAP would necessarily be found to interact,
even if transiently, with the PLC. Surely in the future we
will learn more about how the PLC and ERAAP work, per-
haps even jointly.
Finally, we are quite impressed by howERAAP inhibition
results in enhanced immunogenicity of the cells because
of the emergence of Eun-pMHC I. It is paradoxical that
the absence of a key component of the antigen-process-
ing pathway causes not only the loss but also a gain in the
diversity of the pMHC I repertoire. Learning more about
the structure and regulation of Eun-pMHC I might even
permit novel approaches to cancer immunotherapy as
well as autoimmunity.
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